Penumbra shares surged 14% premarket after Boston Scientific agreed to acquire the medical device maker in a cash-and-stock deal valuing it at $14.5 billion. The acquisition expands Boston Scientific healthcare portfolio, though its own shares dipped nearly 3% premarket. Retail traders turned extremely bullish on Penumbra following the announcement.